Figure 2.

Individual subject parasitemia profiles. Subjects were inoculated intravenously with Plasmodium falciparum–infected erythrocytes on day 0 and were administered a single oral dose of 40-mg (A) or 80-mg (B) MMV390048 on day 8 (indicated by the vertical dashed line). Artemether/lumefantrine (A/L) was administered in response to recrudescence of parasitemia or approximately 25 days post-MMV390048 dosing if recrudescence was not observed. The parasitemia profile for 1 subject in the 80-mg dose cohort who was not dosed with MMV3900048 and was treated instead with A/L is not shown.